Immunogenicity and tolerance of H. influenzae type b, tetanus toxoid conjugate vaccine given concurrently or in combination.
Indian J Pediatr
;
1997 Nov-Dec; 64(6): 839-47
Article
in English
| IMSEAR
| ID: sea-80603
ABSTRACT
The present prospective, open, controlled, randomised comparative trial was undertaken to evaluate the sero response and side effects of PRP-T Conjugate Vaccine (ACT-HIB) in infants and children aged 2 months and 16-24 months. Fifty four babies aged 2 months formed group A, 56 children aged 16-24 months formed group B. Groups A and B were further subdivided into two sub groups each destined to receive either PRP-T vaccine in association with DPT vaccine at different sites (I) or PRP-T and DPT both vaccines at the same site mixed in the same syringe (II). Group A received 3 doses at 2, 3 and 4 months of age and group B received one dose between 16-24 months. The Geometric mean titres of Anti PRP antibodies observed in primary immunisation schedule (A) and single dose vaccination schedule (B) were comparable and significantly higher to prevaccination titres. A serum anti PRP level of > 1.0 mcg/ml after immunisation is believed to correlate with long term protection. Ninety-six percent of infants in Group A and 98% in Group B achieved titres > 1.0 mcg/ml. The side effects were minimal, local and were comparable between the study and control groups, suggesting that PRP-T vaccine is highly immunogenic and well tolerated in Indian infants and children.
Full text:
Available
Index:
IMSEAR (South-East Asia)
Main subject:
Tetanus
/
Female
/
Humans
/
Male
/
Tetanus Toxoid
/
Sensitivity and Specificity
/
Immunization Schedule
/
Vaccines, Conjugate
/
Vaccines, Combined
/
Haemophilus Vaccines
Type of study:
Controlled clinical trial
/
Diagnostic study
Country/Region as subject:
Asia
Language:
English
Journal:
Indian J Pediatr
Year:
1997
Type:
Article
Similar
MEDLINE
...
LILACS
LIS